Sinopharm says may be able to make over 1 bln coronavirus vaccine doses in 2021

Credit: REUTERS/TINGSHU WANG

China National Pharmaceutical Group (Sinopharm), one of several Chinese firms developing coronavirus vaccines, said it may have the capacity to produce more than 1 billion doses in 2021, Chairman Liu Jingzhen said on Tuesday.

Adds details from media briefing

BEIJING, Oct 20 (Reuters) - China National Pharmaceutical Group (Sinopharm), one of several Chinese firms developing coronavirus vaccines, said it may have the capacity to produce more than 1 billion doses in 2021, Chairman Liu Jingzhen said on Tuesday.

About 60,000 people have received Chinese coronavirus vaccine candidates during Phase III clinical trials, with no serious side effects reported so far, Tian Baoguo, an official at China's Ministry of Science and Technology, said at the same government media briefing.

In addition, hundreds of thousands of people in China have been given experimental trial-stage vaccines as part of an emergency inoculation programme launched in July.

(Reporting by Roxanne Liu and Tony Munroe, editing by Louise Heavens)

((tony.munroe@thomsonreuters.com; +86 10 6627 1288; Reuters Messaging: tony.munroe.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More